Perspective Therapeutics, Inc. (CATX) Stock

Healthcare · Medical Devices · Member of Other US Stocks

Perspective Therapeutics, Inc. (CATX) closed at USD 2.34 on 2026-10-15, a change of -14.3 % over the past year, with a market capitalization of USD 247.71M.

Perspective Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Perspective Therapeutics, Inc. key figures

Previous close

USD 2.34 (2026-10-15)

1-year change

-14.3 %

Market cap

USD 247.71M

Enterprise value

USD 14.8M

P/E ratio (trailing)

-1.63

P/E ratio (forward)

-2.09

EPS (trailing)

-1.33

EPS (forward)

-1.04

PEG ratio

n/a

Price to book

0.76

Revenue growth

-72.1 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.68

Employees

163

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Perspective Therapeutics, Inc. and compare it with other stocks.